Marsala Biotech Inc. is an Oncology company developing new treatments for cancer. The Company's lead technology E10A, is being evaluated in head and neck cancer patients. Currently there are only 2 FDA approved drugs which have significant drawbacks. Phase III clinical trials of E10A are planned for…
Marsala Biotech Inc. is an Oncology company developing new treatments for cancer. The Company's lead technology E10A, is being evaluated in head and neck cancer patients. Currently there are only 2 FDA approved drugs which have significant drawbacks. Phase III clinical trials of E10A are planned for 2013 in China and North America. In addition to a huge commercial potential, E10A would help address this significant unmet medical need.
Marsala's lead product E10A has established potential to treat Head and Neck Cancer, which has a market potential of 3.2 billion USD. E10A also has synergistic effects with other anti-cancer agents. Phase III clinical trials of E10A are planned for 2013 in the US & Canada. In addition we have a novel dual inhibitor drug discovery program in pre-clinical stage, for the treatment of different types of cancer.
Team (1)
Sectors Marsala Biotech, Inc. serves:
Life Sciences
Join Axial's Private M&A Platform
Marsala Biotech, Inc. connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
